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ABSTRACT
Introduction: Small cell lung cancer (SCLC) is a tumor with a poor prognosis, often diagnosed in an
advanced stage. Despite aggressive treatment of early and locally advanced disease, SCLC often
relapses. First line chemotherapy provides good response rates in advanced disease, but progression
free and overall survival are limited. New drugs such as some targeted therapies and immune therapies
are promising in SCLC.
Areas covered: In this review, we discuss the preclinical rationale and trial data for targeted therapies
and immune therapies in SCLC, with a specific focus on clinical trials.
Expert commentary: Lack of identification of clear prognostic and predictive biomarkers has limited the
advances in treatment efficacy. This has most likely been the main cause of failure for compounds tested
so far. Due to the highly mutational profile and the rapid growth pattern of SCLC, immunotherapy
combined with chemotherapy seems the most promising treatment option. Concerning targeted agents,
achievements made so far are small, but DLL3-antibodies or combinations of PARPi and immunotherapy
could be very promising. These promising strategies also need testing in limited disease.
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1. Introduction
Incidence of small-cell lung cancer (SCLC) has declined over
the last years, especially in countries with effective smoking
cessation programs (usually high-income countries); neverthe-
less, it still accounts for approximately 10–15% of all lung
cancer cases [1]. Most importantly, SCLC is the sixth most
common cause of cancer-related mortality [2] and its inci-
dence is increasing in the low- and middle-income coun-
tries [3,4].
The strongest risk factor for developing SCLC is smoking; in an
epidemiologic study, only 2.5% of the SCLC occurred in never-
smokers [5]. Smoking cessation results in a decreased risk, but
the risk remains higher compared to never-smokers [6–8].
Low-dose computed tomography screening for SCLC has
not proven to be effective because of the highly aggressive
nature of the disease [9–11]: up to 86% is diagnosed at an
advanced stage, median overall survival (OS) is only
20.6 months, and no survivors were found at 3 years in a
screening trial [10].
Standard treatment for SCLC has not changed over the last
10–15 years both for limited disease (LD) and extensive dis-
ease (ED). Currently, advised treatment, by European Society
for Medical Oncology (ESMO) guidelines, for patients with LD
is chemoradiation followed by prophylactic cranial irradiation
(PCI); surgery is an option in T1–T2, N0, and M0 patients [12].
Concerning ED, standard of care is platinum-based doublet
with etoposide (in Europe/US) or irinotecan (in Japan) for 4–6
cycles; PCI is an option in these patients [12]. Cisplatin can be
substituted by carboplatin; as in a meta-analysis published in
2012 by Rossi et al., no differences in efficacy was found [13].
Despite the high response rate (RR), most patients relapse
within 6 months. The only approved second-line treatment in
Europe and the USA is topotecan either intravenous or oral
(similar efficacy) [14,15]. For those patients that instead pro-
gress after 6 months, a valid option is rechallenge with a
platinum-based regimen.
Among other possible options, paclitaxel showed a RR of
24–29% in two small studies (N = 21 and N = 24), median OS
was only 3.3 months in one trial and 5.8 months in the other trial
[16,17]; temozolomide monotherapy showed a RR of 12–23% in
two small trials, median OS was 5.8 months in both trials [18,19].
CAV still remains also an option although very limited due to its
toxicity profile [12].
Amrubicin, approved in Japan, did not demonstrate an OS
benefit compared to topotecan in the phase III European trial:
median OS was 7.5 months for amrubicin and 7.8 months for
topotecan (HR 0.88, p = 0.17), although in a subset analysis
including platinum-refractory patients a numerically, signifi-
cant OS improvement was found (6.2 vs 5.7 months, HR 0.77,
p = 0.47) [20].
In this review, we will focus on the current evidence for
targeted agents and immunotherapy trials and also give some
insight on the promising compounds that might hopefully
change the poor prognosis of the SCLC patient population.
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2. Targeted therapy in SCLC
2.1. Preclinical rationale
2.1.1. Molecular alterations
The druggable alterations that are found in NSCLC are generally
very rare in SCLC. For example, epidermal growth factor recep-
tor (EGFR), anaplastic lymphoma kinase, human epidermal
growth factor receptor 2, cMET, v-RAF murine sarcoma viral
oncogene homolog-B (BRAF), and c-ROS oncogene 1 (ROS1)
mutations/translocations are rarely found in SCLC samples
[21,22]. Alterations more often found in SCLC are aberrations
in cell cycle regulation (e.g. CDKN2A, CDK4/6, TP53, RB1, Chk-1,
Wee-1), receptor kinase signaling [e.g. stem-cell factor receptor
tyrosine kinase (c-KIT), PI3K/AKT/mTOR, insulin-line growth fac-
tor receptor (IGFR1), fibroblast growth factor receptor 1 (FGFR1),
PTEN, hedgehog signaling pathways], overexpression of the
antiapoptotic proteins (e.g. BCL-2, found in 80% of SCLC), and
alterations in DNA repair pathways [e.g. MYC amplification,
overexpression of poly(ADP ribose) polymerase (PARP)
enzymes, DNA alkyltransferase (O(6)-methylguanine-DNA
methyltransferase (MGMT)) expression] [23–30]. In contrast to
other tumors, mutations in DNA repair genes (such as BRCA1/2)
were not associated with response to PARP inhibition in SCLC.
However, Schlafen11 (SLFN11) which regulates response to
DNA damage and replication stress is a possible predictive
marker for response to PARP inhibition in SCLC, although pro-
spective validation is needed [31]. Furthermore, epigenetic pro-
cesses are also often dysregulated in SCLC (e.g. histone modifier
mutations) [32]. An overview of the incidence of these altera-
tions can be found in Sharp et al. [28]. Reduced SCLC tumor
growth has been shown in preclinical models when the altera-
tions mentioned above are targeted with monotherapies or
combination therapies [33–40].
Another interesting target in SCLC is the NOTCH-signaling
pathway, involved in early lung development and stem-cell
self-renewal. NOTCH signaling can have oncogenic or tumor-
suppressive effects andNOTCH can influencemultiple oncogenic
pathways. The function is dependent on the cellular content and
tumor type; in neuro-endocrine tumors, NOTCH signaling sup-
presses oncogenesis and tumor growth [29,30,41–43]. One of the
NOTCH inhibitory ligands is delta-like ligand 3 (DLL3), which is
overexpressed in approximately 69% of SCLC but not in normal
tissue [29,30]. This DLL3 overexpression is caused by achaete–
scute homologue 1 (ASCL1 or ASH-1) which regulates NOTCH-
signaling components [44,45]. ASH-1 is a master regulator
required for growth and survival of SCLC cells [46] and is
expressed when the tumor-suppressor genes TP53 and RB1 are
inactivated. Bi-allelic inactivation of the tumor-suppressor genes
TP53 and RB1 occurs in almost al SCLC cases [29]. Preclinically,
therapy with a DLL3-targeting antibody–drug conjugate (ADC)
resulted in killing of SCLC cells, especially when they were
expressing DLL3 [47].
SCLC can be divided into three distinct molecular subtypes by
gene-expressing profiles, based on expression of ASH-1 and neu-
rogenic differentiation factor 1 (NEUROD1, a neuronal master
regulator) [44]. The classic SCLC form (‘neuroendocrine high’) is
characterized by ASH-1 expression, the classic/variant type (‘neu-
roendocrine variable’) by high NEUROD1 expression with or
without ASH-1 expression. The last form (variant/‘neuroendocrine
negative’) is rare and has no expression of these two markers
[44,48,49]. The different forms might respond different to immune
therapies [50]. Last, although the majority of SCLC patients have
mutant RB1, some have wild-type RB1, with varying percentages
reported in the literature [29,51]. RB1 status is important, as
patients with wild-type RB1 have lower responses to chemother-
apy [51], and mutant RB1 status has been associated with sensi-
tivity to DNA-damaging agents [52].
2.1.2. Angiogenesis
Besides the abovementioned alterations, the vasculature can
also be targeted in SCLC as SCLC is a highly angiogenic tumor
[53–55]. Compared with healthy controls, vascular endothelial
growth factor (VEGF) and ang-2 (angiogenesis mediator) are
increased in SCLC patients [56,57]. SCLC cell lines also express
VEGF-receptor (VEGFR) 2 and 3 [54]. Furthermore, a high level
of circulating VEGF is associated with poor OS and poor
response to treatment [58,59].
2.1.3. Other targets
Essential for tumor growth are sterols and isoprenoids that are
produced by the mevalonate pathway; cholesterol is a compo-
nent of this pathway (reviewed in Mullen et al.) [60].
Preclinically, it has been shown that statins can inhibit SCLC
growth, either alone or in combination with chemotherapy [61].
Matrix metalloproteinases (MMPs) are a family of secreted
proteins that are capable of digesting extracellular matrix and
basement membrane components. MMP expression is often
detected in SCLC and elevated expression has been associated
with worse OS [62]. Preclinically, MMP inhibitors were able to
reduce tumor growth [63,64].
Trophoblast cell-surface antigen (Trop-2) is a glycoprotein
that is elevated in many types of cancer, including SCLC.
Elevated Trop-2 stimulates cancer growth and is associated
with a worse prognosis. Preclinically, an ADC against Trop-2
showed activity in several cancers including SCLC [65].
2.2. Trial data with targeted agents in LD-SCLC
The majority of trials have evaluated targeted therapy in
advanced SCLC. The few that have tested targeted therapies
in LD-SCLC are summarized in Table 1; those that included LD-
SCLC as well as ED-SCLC patients are summarized only in this
section and not in the ED-SCLC section. Ongoing trials are
summarized in Table 2.
2.2.1. Angiogenesis
Thalidomide has antiangiogenic properties and has been eval-
uated in a randomized, double-blind, placebo-controlled trial
(N = 724), including both LD- (51%) and ED-SCLC patients.
Primary end point was OS. Median OS was 10.5 months for
placebo and 10.1 months for thalidomide [HR (95% CI) 1.09
(0.93–1.27); p = 0.28]. Patients treated with thalidomide had a
significantly higher risk of having a tromboembolic event
(p < 0.001) [66].
Vandetanib is another antiangiogenic agent as well as an
EGFR inhibitor and was tested as maintenance therapy in a
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double-blind randomized phase II trial (N = 107), including LD-
(43%) as well as ED-SCLC patients. Vandetanib did not improve
progression-free survival (PFS) (primary end point): median 2.7
(vandetanib) versus 2.8 (placebo) months, respectively [HR (80%
CI) 1.01 (0.75–1.36); p = 0.51]. Median OS (a secondary end
point) was also not significantly different: 10.6 months for
vandetanib versus 11.9 for placebo [HR (80% CI) 1.43 (1.00–
2.05); p = 0.9] [67]. In both trials, also the subgroup of LD-SCLC
patients did not derive benefit in the experimental arm [66,67].
2.2.2. Other targets
In the multicenter, phase III, randomized, double-blind, pla-
cebo-controlled LUNGSTAR trial (N = 846, 43% LD-SCLC), pra-
vastatin 40 mg once daily or placebo was added to standard-
of-care first-line treatment (chemoradiation for LD-SCLC, plati-
num–etoposide for ED-SCLC). Pravastatin did not significantly
improve OS (primary end point): for LD patients, median OS
was 14.6 months for the pravastatin group and 14.6 months
for the placebo group [HR (95% CI) 0.96 (0.76–1.20);
p = 0.71] [68].
Adjuvant marimastat (10 mg orally bid), a MMP inhibitor, has
also been evaluated in a randomized, double-blind, placebo-
controlled phase III trial (N = 532, 54% LD-SCLC). The trial was
negative: median OS was 9.3 months for marimastat and
9.7 months for placebo [HR (95% CI) 1.01 (0.83–1.23);
p = 0.90]. In an unplanned analysis, there was also no survival
benefit for marimastat for the LD patients [69].
2.3. Trial data with targeted agents in ED-SCLC
2.3.1. Molecular alterations
Tyrosine kinase receptor inhibitors inhibiting cell signaling and/
or apoptosis, with or without targeting angiogenesis (e.g. ima-
tinib, dasatinib, gefitinib, linsitinib, sorafenib, sunitinib, cedira-
nib, nintedanib, and pazopanib), all failed to show a significant
benefit in SCLC (reviewed in Sharp et al. [28] and Baize et al.
[70]). More promising targets are summarized in Table 1 and
ongoing trials are summarized in Table 2.
2.3.2. PARP inhibitors
Temozolomide, an alkylating agent prodrug, showed some
activity in a single-arm phase II trial (N = 64): ORR was 23%
in the platinum-sensitive cohort (N = 48) and 13% in the
platinum refractory cohort. However, median PFS was only
3.5 months [18]. There was a trend to a higher ORR in patients
with MGMT promotor methylation: 38% versus 7% (p = 0.08).
Resistance to temozolomide can be PARP-based and there is
preclinical evidence that PARP inhibitors (PARPi) act synergisti-
cally with temozolomide [37,71]. Therefore, veliparib (PARPi)
40 mg orally twice daily on day 1–7 (28-day cycle) combined
with temozolomide 150–200 mg/m2/day orally once daily on
dag 1–5 was tested in a randomized, double-blind, placebo-
controlled phase II trial including ED-SCLC patients eligible for
second/third-line treatment (N = 104). The trial was negative for
its primary end point: 4-month PFS was 36% for veliparib/temo-
zolomide and 27% for placebo/temozolomide (p = 0.19). Median
OS was also not significantly different also (8.2 vs 7 months,
respectively, 95% CI 5.3–9.5, p = 0.50). Nevertheless, the combi-
nation resulted in a significantly higher ORR (39%) compared to
temozolomide-placebo (ORR 14%) (p = 0.016) at the price of a
higher percentage of grade 3 and 4 thrombocytopenia and
neutropenia (50% vs 9%, 31% vs 7%, respectively). In the explora-
tory biomarker analysis, in the subset of patients tested for
PARP1 and/or MGMT methylation, no association between
PARP1 positivity or MGMT methylation and ORR was found.
Interestingly, patients with SLFN11 expression had improved
PFS and OS with the veliparib/temozolomide combination [72].
As this analysis was exploratory, further evaluation is necessary
to determine whether SLFN11 expression could serve as a bio-
marker to select SCLC patients for therapy with PARPi. Of note, a
new biopsy should be obtained after chemotherapy, as SLFN11
decreases after exposure to chemotherapy [72].
Furthermore, it is possible that the combination with a
PARPi and a PI3K-inhibitor would be a better combination,
as SCLC can escape PARPi by upregulation of the PI3K–AKT–
mTOR pathway [33]. To the best of our knowledge, no trials
have been completed or are currently ongoing with this com-
bination. Everolimus (a PI3K-inhibitor) monotherapy had lim-
ited activity [73]. Trials with veliparib added to platinum–
etoposide are currently open (NCT01642251 and phase II
part of NCT02289690), as veliparib potentiated the effect of
platinum–etoposide preclinically and was shown to be safe in
a phase I trial [74]. Olaparib is also a PARPi, and several trials of
monotherapy olaparib or in combination with another drug
are ongoing.
Another interesting combination is the combination of a
PARPi and a Wee1 inhibitor: in a preclinical model, olaparib
combined with the Wee1 inhibitor AZD1775 was more effica-
cious than cisplatin/etoposide in chemosensitive circulating
tumor cell patient-derived explants (CDx), but responses
diminished when the combination was tested at disease pro-
gression, suggestion that it should be tested in the clinic
before disease progression. CDx with defects in DNA repair
genes benefited most [75]. Several trials with monotherapy
AZD1775 or AZD1775 combined with PARPi are ongoing in
SCLC (Table 2).
Last, combination of a PARPi and a cell-cycle inhibitor is
interesting as preclinically, prexasertib (LY2606368), a cell-
cycle checkpoint kinase CHK1 inhibitor, combined with ola-
parib or cisplatin augmented the effects of the other drug,
especially when MYC amplification or overexpression was pre-
sent [76]. A phase II study of monotherapy prexasertib is
ongoing (NCT02735980).
2.3.3. ADCs
ADCs are antibodies directed at a defined antigen on a cancer
cell, linked to a cytotoxic agent. Several are in development for
SCLC treatment. The most advanced are Rovalpituzumab
Tesirine (Rova-T) and Sacituzumab Govitecan (IMMU-132).
Furthermore, Re-188 P2045, a somatostatin analog labeled
with Rhenium-188, showed interesting survival in a phase I trial.
Rova-T recognizes the NOTCH ligand DLL3. In a phase I trial
(NCT01901653), 82 lung cancer patients (74 SCLC, 8 LCNEC),
who progressed after one or more lines of chemotherapy,
were treated with escalating doses of single-agent Rova-T.
About 18% of patients treated at the maximum-tolerated
dose had a confirmed response and 50% had stable disease.
Activity was higher in DLL3-high patients: ORR was 38% and
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disease control rate was 50%. Median OS was 5.8 months in
the DLL3-high group. The safety profile was manageable; most
common grade ≥3 toxicities were thrombocytopenia, pleural
effusion, and increased lipase [77]. Based on these results,
other trials with Rova-T were initiated, mainly in DLL3-high
SCLC patients.
Results of the phase II TRINITY trial have recently been
presented: 339 DLL3-expressing patients were included and
were treated with Rova-T 0.3 mg/kg IV every 6 weeks, for 2
cycles (under specified conditions, retreatment was allowed).
Primary end points were ORR and OS; a prespecified sub-
group analysis included those with high DLL3 expression
(≥75% of cells DLL3 positive). About 66% of patients com-
pleted the planned two doses of Rova-T, and ORR by inde-
pendent review was 12.4% and was 14.3 in the DLL3-high
group (N = 238). In the DLL3-high group, 72% (third-line
Rova-T) and 77% (fourth line) had disease control. Median
OS (95% CI) was similar and was 5.6 (4.9–6.1) months in the
total group and 5.7 (4.9–6.7) months in the DLL3-high group.
Responses (best response and confirmed ORR) were asso-
ciated with improved outcomes, as median OS was
9.8 months for responders. Forty percent of patients had
grade 3 or higher treatment-related adverse event, of interest
were photosensitivity reactions, pleural effusion, peripheral
edema, and pericardial effusion. Other common toxicities
were mainly gastrointestinal. Three percent had fatal events
(edema, pneumonitis, ascites, drug-induced liver injury,
pleural effusion, pneumothorax, respiratory failure, and sep-
sis) [78]. Two other methods of targeting DLL3 are a half-life
extended bi-specific T-cell engager antibody construct
(AMG 757) and adoptive chimeric antigen receptor T-cell
therapy (AMG 119); phase I trials are currently enrolling
(NCT03319940 and NCT03392064, respectively).
IMMU-132 contains the active metabolite of irinotecan,
conjugated to an antibody that binds to Trop-2 which is
widely expressed on SCLC. In a single-arm phase II trial
(NCT01631552), 50 pretreated SCLC patients were treated
with IMMU-132 8 or 10 mg/kg iv on days 1 and 8 of a 21-
day cycle. Primary end points were safety and ORR. Fourteen
percent of patients had confirmed responses; median dura-
tion of response (DOR) was 5.7 months. Most common grade
≥3 toxicities were neutropenia (34%), fatigue (13%), diarrhea
(9%), and anemia (6%). Median OS was 7.5 months and was
not statistically significantly different for those with plati-
num-sensitive or platinum-resistant disease in the overall
population [79].
Re-188 P2045 was tested in a phase I trial, including
advanced NSCLC and SCLC patients expressing somastotatin
receptors (N = 15, of which 14 had ≥2 previous treatment
lines). No responses were seen, but 62.5% had stable disease
for at least 8 weeks, and median OS was 11.5 months which is
unexpectedly long in a pretreated population [80]. However,
to the best of our knowledge, no trials are ongoing with this
compound.
2.3.4. FGFR inhibitors
One trial has completed recruitment, although study results
are not yet available: NCT02109016, a phase 2 study to assess
if lucitanib is safe and effective (ORR) in the treatment of
patients with advanced/metastatic lung cancer and FGFR,
VEGF, or platelet-derived growth factor (PDGF)-related genetic
alterations.
2.3.5. Multikinase inhibitors
Anlotinib is a multikinase inhibitor, especially inhibiting
VEGFR, c-KIT, PDGFR, and FGFR. This drug showed promising
clinical activity in third-line treatment and beyond the rando-
mized, double-blind phase II ALTER1202 trial (NCT03059797).
Patients were randomized 2:1 to anlotinib 12 mg qd orally,
days 1–14 of a 21-day schedule (N = 81), or placebo (N = 38).
Median PFS (primary end point) was significantly prolonged in
the anlotinib arm compared with the placebo arm: 4.1 (95% CI
2.8–4.2) months versus 0.7 (95% CI 0.7–0.8) months [HR 0.19
(95% CI 0.12–0.32), p < 0.001]. OS data were not sufficiently
mature at the date of the first report (WCLC, September 2018).
Toxicity was manageable, with 35.8% versus 15.4% grade 3–5
toxicity (1 death in the anlotinib group possibly related to
anlotinib). The most common grade ≥3 toxicity was hyperten-
sion (13.6%), followed by hand–foot syndrome (4.9%), hyper-
triglyceridemia (3.7%), and lymphopenia (2.5%) [81]. Anlotinib
is currently being tested as maintenance therapy after four
cycles of lobaplatin/etoposide in a randomized phase II trial
(NCT03700359).
2.3.6. Aurora kinase inhibitors
Aurora kinase A is necessary for mitotic spindle formation.
MYC, a transcriptional regulator of aurora kinases A and B, is
amplified in 9–20% of SCLCs [82,83]; these SCLCs have a
growth advantage in the absence of p53 [84]. Alisertib, an
aurora kinase inhibitor, showed promising results in a phase
I/II trial-included patients with pretreated solid cancer. Primary
end point was ORR. Alisertib was given at a dose of 50 mg
twice daily, for 7 days followed by a break of 14 days. In the
subgroup of SCLC patients (N = 60, of which 48 were response
evaluable), an ORR of 21% was found. Thirty-six SCLC patients
had platinum-sensitive disease and 12 had platinum-resistant
disease; the highest ORR was found for platinum-refractory
patients (25% vs 19%). DOR was 3.1 months for platinum-
sensitive patients and 4.3 months for platinum-resistant
patients. Most common grade 3–4 adverse events were neu-
tropenia (43%), leukopenia (21%), and anemia (10%) [85].
Aurora A functional single nucleotide polymorphisms were
associated with improved outcome in patients with solid
tumors treated with alisertib [86]. Based on these results, a
randomized phase II study was initiated in advanced SCLC,
evaluating second-line paclitaxel with alisertib or placebo.
Patients were stratified according to platinum-sensitive or
refractory disease and the presence of brain metastases.
Primary end point was PFS. Alisertib was given at a dose of
40 mg twice daily orally, 3 days on/4 days off. When combined
with alisertib, paclitaxel was given at a dose of 60 mg/m2 iv on
days 1, 8, and 15 of a 28-day schedule. When combined with
placebo, paclitaxel was given a dose of 80 mg/m2. A total of
178 patients were enrolled: median PFS was significantly higher
in the investigational arm and was 3.2 versus 2.2 months [cor-
rected HR (95% CI) 0.71 (0.51–0.99); p = 0.038]. In the platinum-
resistant group (N = 109), median PFS was also significantly
higher in the investigational arm: 2.9 vs 1.6 months [HR (95% CI)
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0.66 (0.44–0.98); p = 0.037]. ORR was slightly higher in the
alisertib/paclitaxel group: 22% versus 18%. There was a trend
to a significantly higher median OS in the investigational arm:
6.9 versus 5.6 months [HR ((95% CI) 0.73 (0.52–1.02); p = 0.064].
Treatment-related grade ≥3 adverse events were higher in the
alisertib/paclitaxel group: 67% versus 25%; main adverse events
(all grades) were hematological and gastrointestinal. However,
health-related quality of life was similar for both groups. In an
exploratory analysis, patients with c-MYC expression benefited
most from the combination while the opposite was found for
the c-MYC-negative group. For the c-MYC-positive group, med-
ian PFS was 4.6 months for the combination and 2.3 months for
paclitaxel [HR (95% CI) 0.29 (0.12–0.72)]. For the c-MYC-negative
groups, median PFS was 3.3 and 5.2 months, respectively [HR
(95% CI) 11.9 (1.52–91.2)] [87].
Barasertib (AZD1152), another aurora kinase inhibitor,
showed promising preclinical results in SCLC [88], and only
one trial is ongoing NCT01935336 (Table 2).
2.3.7. Lurbinectedin
Lurbinectedin inhibits active transcription in tumor cells and
acts synergistically with doxorubicin. In a phase I trial including
relapsed SCLC patients, recommended phase II dose was dox-
orubicin 50 mg/m2 iv on day 1 of a 21-day schedule and
lurbinectedin 4.0-mg flat dose iv on the same day. After reach-
ing a cumulative dose of 450 mg/m2 doxorubicin, patients were
switched to lurbinectedin 7.0-mg flat dose to avoid doxorubicin
cardiomyopathy. Twenty-seven SCLC patients were evaluable.
Toxicity profile was manageable; grade 4 toxicities were only
hematological (79% neutropenia), grade 3 toxicities were also
mainly hematological, with also in a low percentage of patients
liver test abnormalities, fatigue, infections, mucositis, and elec-
trolyte disturbances. Second-line RR in platinum-sensitive dis-
ease were as high as 91.7% with a median PFS of 5.8 months; in
platinum-resistant disease, RR was 33.3% with a median PFS of
3.5 months. Third-line RR was 20%, with a median PFS of
1.2 months [89]. Lurbinectedin plus doxorubicin is currently
compared to cyclophosphamide/doxorubicin/vincristin or topo-
tecan in the ATLANTIS trial (NCT02566993).
2.3.8. Stem-cell inhibitors
Hedgehog inhibitors have also been evaluated in SCLC as the
Hedgehog pathway has been implicated in SCLC tumor initia-
tion and progression. In a phase I trial (N = 15 newly diagnosed
ED-SCLC patients), the hedgehog inhibitor sonidegib (LDE225)
was combined with cisplatin/etoposide. About 800 mg sonide-
gib daily was the recommended phase II dose. The most com-
mon grade 3 toxicities were anemia, neutropenia, CPK
elevation, nausea, and fatigue. About 79% of patients had
partial responses, and one patient with SOX2 amplification
(reported to drive hedgehog signaling) remained progression
free on maintenance sonidegib after 27 months [90]. Currently,
no trials are ongoing on clinicaltrials.gov in SCLC.
Vismodegib, another hedgehog inhibitor, was tested in a
randomized phase II trial (E1508), including 152 treatment-
naive advanced SCLC patients. Patients were randomized to
standard chemotherapy, or standard chemotherapy combined
with vismodegib 150 mg/day orally or cixutumumab (insulin-
like growth factor 1 receptor antibody). Primary end point was
PFS: the trial was negative with a HR (95% CI) for vismodegib-
chemo versus chemo: 0.98 (0.65–1.47) (p = 0.45). The addition
of vismodegib did not increase the percentage of grade ≥3
adverse events [91].
One more trial has completed recruitment but results are
not yet available: NCT01579929, a phase I trial of the combina-
tion of LDE225, with etoposide and cisplatin as first-line treat-
ment of ED-SCLC.
2.3.9. Angiogenesis inhibition
Several trials have attempted to incorporate an angiogenesis
inhibitor in the treatment of SCLC but all failed to show an OS
improvement despite sometimes an improvement in PFS.
Adding bevacizumab after response to two cycles of induc-
tion chemotherapy did not result in an improved median PFS in
the IFCT 0802-phase II–III trial (NCT00930891) [92]. Based on,
among others, the positive PFS results of the phase II SALUTE
trial (NCT00403403, first-line chemotherapy ± bevacizumab, fol-
lowed by maintenance bevacizumab or placebo) [93], the phase
III GOIRC-AIFA FARM6PMFJM trial (EudraCT No. 2007-007949-13,
N = 204) was launched, with a similar design as the SALUTE
trial. The study failed its primary end point as median OS was
8.9 months for the placebo group and 9.8 months for the
bevacizumab group (HR 0.78, 95% CI 0.58–1.06, p = 0.113).
However, in a subgroup analysis, patients who received main-
tenance bevacizumab (43% in the EP + bevacizumab group)
had a statistically significant superior OS; so, continuation of an
angiogenesis inhibitor across all lines might be an option [94].
Trials with other angiogenesis inhibitors (nintedanib, thalido-
mide, sunitinib, vandetanib) also failed to improve OS
[66,67,95,96]. Based on these results, an angiogenesis inhibitor
should only be administered to SCLC patients in the context of
a clinical trial. Ziv-aflibercept binds circulating VEGF and might
represent a new treatment option to improve outcome in SCLC.
However, when added to topotecan in a phase II trial, only PFS
but not OS improved, at a cost of increased toxicity [97].
Bevacizumab added to paclitaxel, topotecan, or irinotecan also
failed to improve outcome in relapsed SCLC patients [98–100].
3. Immunotherapy in SCLC
3.1. Preclinical rationale
SCLC has a high rate of somatic mutations: non-synonymous
mutation rates of up to 8.6 mutations per million base pairs
have been found [29,32]. They are often induced by smoking:
benzo(a)pyrene (a carcinogenic compound of tobacco) and its
active metabolite covalently binds to DNA, which can result in
a DNA synthesis block leading to aberrant centrosome ampli-
fication. In turn, this can lead to abrogated p53 function and
chromosome 3p deletion (which contains multiple tumor sup-
pressor genes) [101–103]. This loss of tumor suppressor genes
leads to increased mutagenesis. In 25% of SCLC patients, C:
G > A:T transversions are found and they are an indication of
heavy smoking [29,104]. Moreover, aberration of the intrinsic
apoptotic pathway by inversion of the Bcl-2/Bax ratio results in
further tumor growth [105]. Another signature found in SCLC
which is linked to smoking and an increased mutagenesis is
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the apolipoprotein B mRNA editing enzyme, catalytic polypep-
tide-like (APOBEC) signature [106].
A high tumor mutational burden (TMB) has been associated
with a favorable outcome when treated with immune check-
point inhibitors. As SCLC has a high mutational burden, this
provides opportunities for the immune system to recognize
and attack the tumor cells [107]. Furthermore, approximately
15–30% of SCLCs express PD-L1 [108], and PD-L1 expression is
often associated with higher RR in other tumors such as NSCLC
[109]. Evidence that SCLC induces an immune response can be
found in the relatively high incidence of paraneoplastic syn-
dromes neoplastic-trigged autoimmune diseases in SCLC [110].
Moreover, SCLC patients in which immune activity is shown have
a better outcome. For example, a higher CD45+ T-cell count was
associated with improved prognosis (irrespective of stage and
performance status) [111]. High effector T-cell counts were more
often found in LD-SCLC compared to ED-SCLC, and higher effec-
tor-to-regulatory T-cell ratios were associated with improved
outcome [112,113]. Immune checkpoint inhibitors are now incor-
porated in the treatment strategy of advanced NSCLC, either in
first line or beyond [109,114–116]. Furthermore, in the PACIFIC
trial (NCT02125461) maintenance, durvalumab (anti-PD-L1 anti-
body) showed a PFS benefit in stage III NSCLC patients treated
with concurrent CRT, compared to placebo [117]. Trial data for
SCLC are discussed below.
3.2. Trial data with immunotherapy in LD-SCLC
Currently, there are only completed vaccination trials and
interferon trials, but no completed checkpoint inhibitor trials
in LD-SCLC. Results from trials including LD as well as ED-SCLC
patients will be discussed in the LD-SCLC section. Completed
trials are summarized in Table 3 and ongoing trials are sum-
marized in Table 4.
3.2.1. Vaccination trials in LD-SCLC
So far, results with vaccination have been disappointing. In a
randomized phase III trial, LD-SCLC patients responding to
chemoradiation were randomized between five vaccinations
of Bec2 (2.5 mg)/BCG vaccine or observation. Bec2 is an anti-
idiotypic antibody that mimics GD3. GD3 is expressed on the
surface of tumor cells. Primary end point was OS and 515
patients were randomized. The study was negative for its pri-
mary end point: median OS was 14.3 months for the observa-
tion arm and 16.5 months for the vaccination arm [HR (95% CI)
1.12 (0.91–1.37); p = 0.28] [118].
In a phase I trial (N = 16), vaccination of SCLC patients (LD
and ED-SCLC) with a major response to their initial therapy
with synthetic fucosyl GM-1 conjugated to keyhole limpet
hemocyanin at different dose levels was safe and induced an
IgM-antibody response. However, no radiological responses
were observed [119]. Another phase I trial vaccinated SCLC
patients (N = 18, LD and ED-SCLC) responding to initial ther-
apy, with a polySA vaccine. PolySA is a polymer side chain
bound to the neural cell adhesion molecule that is extensively
expressed on the surface of SCLC cells. The vaccine was safe
and antibody responses were documented but radiological
responses were not provided. Median OS was 22.9 months
rather encouraging in this patient population [120].
The two ongoing vaccination trials in LD-SCLC have been
terminated: NCT00776295: autologous SCT followed by den-
dritic cell p53 vaccination, terminated because of low accrual;
NCT00045617: Chemoradiation and monoclonal antibody
11D10 or anti-idiotype monoclonal antibody GD2 anti-idiotype
vaccine, terminated because of lack of drug availability.
3.2.2. Immunotherapy trials in LD-SCLC
Interferon (IFN) therapy has been evaluated in SCLC. IFNs have
immunoregulatory, antiangiogenic, and antiproliferative effects.
In a randomized phase II trial including 164 chemo-naive SCLC
patients (62 LD-SCLC), patients were randomized to chemother-
apy alone (group A), or chemotherapy combined with IFN-alfa
(group B), IFN-gamma (group C), or both IFN-alfa and IFN-gamma
(group D). The trial was negative for its primary end point:
median OS for group A–D was 10.0, 10.3, 8.3, and 11 months,
respectively (p > 0.05). When compared to the other groups,
median OS was significantly higher for LD-SCLC patients treated
in group B: median OS for group B was 34 versus 19 months for
group A (p = 0.039), 13.6 months for group C (p < 0.005), and
17months for group D (p = 0.038). However, number of LD-SCLC
patients per group was small [121].
3.2.3. Checkpoint inhibitors
The concept of maintenance checkpoint inhibition is currently
also tested in limited-stage SCLC in several trials; these are
summarized in Table 4.
3.3. Trial data with immunotherapy in ED-SCLC
3.3.1. Vaccination trials in ED-SCLC
Besides the trials that included LD-SCLC as well as ED-SCLC
(summarized in the LD-SCLC section), three other vaccination
trials included only ED-SCLC patients. In a single-arm phase II
trial (N = 10 pretreated SCLC patients), a personalized peptide
vaccination was tested. The antigens in the vaccine were
selected based on preexisting host immunity. The vaccine was
administered weekly for 6 weeks and biweekly thereafter. Four
patients discontinued during the weekly vaccination due to
rapid disease progression; for the other six patients, peptide-
specific immunological boosting was observed. At data-lock,
two patients were still alive (survival 24.5 and 10 months);
survival of the other patients was 25.0, 9.5, 6.5, and 6 months
[122]. A similar phase II study included 46 ED-SCLC patients
(pretreated and treatment-naive). The treatment was safe, and
median OS was improved in those with increased IgG responses
to a greater number of nonvaccinated peptides after the sec-
ond cycle of vaccination (40.7 vs 12.6 months, p = 0.010) [123].
As the p53 gene is mutated in approximately 90% of SCLC,
a vaccine consisting of dendritic cells transduced with the full-
length wild-type p53 gene delivered via an adenoviral vector
has been evaluated in ED-SCLC patients (N = 29). Vaccines
were given at two-weekly intervals. About 57% had p53-spe-
cific T-cell responses, but only one patient responded clinically
while the others progressed. Interestingly, 62% of patients
responded to chemotherapy that immediately followed the
EXPERT REVIEW OF ANTICANCER THERAPY 159
Ta
bl
e
3.
Co
m
pl
et
ed
tr
ia
ls
w
ith
im
m
un
e
th
er
ap
ie
s
in
SC
LC
.
Au
th
or
,y
ea
r
Tr
ea
tm
en
t
Tr
ia
lt
yp
e
N
SC
LC
Pr
im
ar
y
st
ud
y
ob
je
ct
iv
e
O
ut
co
m
e
V
ac
ci
na
ti
on
tr
ia
ls
G
ia
cc
on
e,
20
05
[1
18
]
Be
c2
/B
CG
va
cc
in
e
or
ob
se
rv
at
io
n
af
te
r
re
sp
on
se
to
CR
T
Ph
as
e
III
51
5
O
nl
y
LD
O
S
M
ed
ia
n
O
S
14
.3
m
(o
bs
er
va
tio
n)
vs
16
.5
m
(v
ac
ci
na
tio
n)
H
R
(9
5%
CI
)
1.
12
(0
.9
1–
1.
37
);
p
=
0.
28
Kr
ug
,2
00
4
[1
19
]
Sy
nt
he
tic
fu
co
sy
lG
M
-1
co
nj
ug
at
ed
to
ke
yh
ol
e
lim
pe
t
he
m
oc
ya
ni
n
va
cc
in
e
af
te
r
m
aj
or
re
sp
on
se
to
in
iti
al
tr
ea
tm
en
t
Ph
as
e
I
16
ED
an
d
LD
Es
ta
bl
is
h
th
e
lo
w
es
t
ef
fe
ct
iv
e
do
se
ca
pa
bl
e
of
in
du
ci
ng
an
tib
od
y
pr
od
uc
tio
n
Lo
w
es
t
do
se
10
µg
N
o
re
sp
on
se
s
Kr
ug
,2
01
2
[1
20
]
Po
ly
SA
va
cc
in
e
af
te
r
re
sp
on
se
to
in
iti
al
tr
ia
l
Ph
as
e
I
18
ED
an
d
LD
Cf
Kr
ug
20
04
,a
ls
o
sa
fe
ty
Lo
w
es
t
do
se
10
µg
6%
gr
ad
e
3
to
xi
ci
ty
N
o
re
sp
on
se
s
Te
ra
za
ki
,2
01
2
[1
22
]
Pe
rs
on
al
iz
ed
pe
pt
id
e
va
cc
in
at
io
n
Ph
as
e
II
Si
ng
le
ar
m
10 ED
Im
m
un
ol
og
ic
al
re
sp
on
se
s
Im
m
un
ol
og
ic
al
bo
os
tin
g
in
th
e
6
pa
tie
nt
s
th
at
re
ce
iv
ed
at
le
as
t
on
e
cy
cl
e
(6
va
cc
in
at
io
ns
)
Sa
ka
m
ot
o,
20
17
[1
23
]
Pe
rs
on
al
iz
ed
pe
pt
id
e
va
cc
in
at
io
n
Ph
as
e
II
Si
ng
le
ar
m
46 ED
Fe
as
ib
ili
ty
2%
gr
ad
e
3
to
xi
ci
ty
70
%
an
d
95
%
Pe
pt
id
e-
sp
ec
ifi
c
Ig
G
re
sp
on
se
s
to
th
e
va
cc
in
at
ed
pe
pt
id
es
af
te
r
1
an
d
2
cy
cl
es
,r
es
pe
ct
iv
el
y
An
to
ni
a,
20
06
[1
24
]
D
en
dr
iti
c
ce
lls
tr
an
sd
uc
ed
w
ith
th
e
fu
ll-
le
ng
th
w
ild
-t
yp
e
p5
3
ge
ne
va
cc
in
e
29 ED
Ev
al
ua
te
im
m
un
ol
og
ic
al
an
d
cl
in
ic
al
ef
fe
ct
s
of
va
cc
in
e
57
%
ha
d
p5
3-
sp
ec
ifi
c
T-
ce
ll
re
sp
on
se
s
O
RR
3%
IF
N
-b
as
ed
tr
ia
ls
Za
ro
go
ul
id
is
,2
01
3
[1
21
]
CT
,C
T
+
IF
N
-a
lfa
or
CT
+
IF
N
-g
am
m
a
or
CT
+
IF
N
A-
al
fa
+
ga
m
m
a
Ph
as
e
II
16
4
(3
8%
LD
)
O
S
M
ed
ia
n
O
S
10
.0
,1
0.
3,
8.
3,
an
d
11
m
,r
es
pe
ct
iv
el
y
(p
>
0.
05
)
Pi
lla
i,
20
14
[1
25
]
Pa
cl
ita
xe
l+
IF
N
-a
lfa
+
13
-C
RA
Ph
as
e
II
37
O
RR
O
RR
9%
M
ed
ia
n
PF
S
2.
0
m
C
he
ck
po
in
t
in
hi
bi
to
r
tr
ia
ls
in
ED
-S
C
LC
Re
ck
,2
01
6
[1
26
]
CT
+
ip
ili
m
um
ab
or
pl
ac
eb
o
Ph
as
e
III
D
ou
bl
e
bl
in
d
11
32
95
4
re
ce
iv
ed
st
ud
y
dr
ug
/p
la
ce
bo
O
S
in
pa
tie
nt
s
th
at
re
ce
iv
ed
at
le
as
t
1
do
se
of
st
ud
y
dr
ug
/p
la
ce
bo
M
ed
ia
n
O
S
11
.0
m
(ip
ili
m
um
ab
)
vs
10
.9
m
(p
la
ce
bo
)
H
R
0.
94
,9
5%
CI
0.
81
–1
.0
9,
p
=
0.
38
O
tt
,2
01
7
[1
27
]
Pe
m
br
ol
iz
um
ab
in
PD
-L
1
ex
pr
es
si
ng
(≥
1%
)
pa
tie
nt
s
Ph
as
e
I
24
Sa
fe
ty
4%
gr
ad
e
5
to
xi
ci
ty
(c
ol
iti
s)
4%
gr
ad
e
3
to
xi
ci
ty
O
RR
33
%
M
ed
ia
n
PF
S
1.
9
m
,m
ed
ia
n
O
S
9.
7
m
G
ad
ge
el
,2
01
8
[1
28
]
Pe
m
br
ol
iz
um
ab
m
ai
nt
en
an
ce
Ph
as
e
II
Si
ng
le
ar
m
45
PF
S
fr
om
st
ar
t
m
ai
nt
en
an
ce
O
RR
11
.8
%
m
ed
ia
n
PF
S
1.
4
m
,m
ed
ia
n
O
S
9.
4
m
Ch
un
g,
20
18
[1
29
]
Pe
m
br
ol
iz
um
ab
se
co
nd
lin
e
an
d
be
yo
nd
Ph
as
e
II
Si
ng
le
ar
m
10
7
O
RR
O
RR
18
.7
%
O
RR
PD
-L
1
po
si
tiv
e
vs
PD
-L
1
ne
ga
tiv
e,
35
.7
%
vs
6.
0%
G
ol
dm
an
,2
01
8
[1
30
]
D
ur
va
lu
m
ab
se
co
nd
lin
e
an
d
be
yo
nd
Ph
as
e
II
Si
ng
le
ar
m
21
Sa
fe
ty
O
RR
N
o
gr
ad
e
≥
3
to
xi
ci
tie
s
O
RR
9.
5%
M
ed
ia
n
PF
S
1.
9
m
,m
ed
ia
n
O
S
4.
8
m
Bo
nd
ar
en
ko
,2
01
8
[1
37
]
D
ur
va
lu
m
ab
+
tr
em
el
im
um
ab
fo
llo
w
ed
by
du
rv
al
um
ab
m
ai
nt
en
an
ce
Ph
as
e
II
21
O
RR
O
RR
9.
5%
M
ed
ia
n
PF
S
1.
9
m
on
th
s
M
ed
ia
n
O
S
6.
0
m
on
th
s
An
to
ni
a,
20
16
[1
34
]
N
iv
ol
um
ab
or
ni
vo
lu
m
ab
+
ip
ili
m
um
ab
fo
llo
w
ed
by
ni
vo
lu
m
ab
m
ai
nt
en
an
ce
Ph
as
e
I/I
I
3-
ar
m
21
6
Sa
fe
ty
O
RR
O
RR
ni
vo
lu
m
ab
m
on
ot
he
ra
py
10
%
O
RR
ni
vo
lu
m
ab
+
ip
ili
m
um
ab
19
–3
3%
O
ut
co
m
es
im
pr
ov
ed
in
TM
B-
hi
gh
gr
ou
p
Pu
jo
l,
20
18
[1
31
]
At
ez
ol
iz
um
ab
or
st
an
da
rd
ch
em
ot
he
ra
py
Ph
as
e
II
Ra
nd
om
iz
ed
no
nc
om
pa
ra
tiv
e
73
O
RR
O
RR
at
ez
ol
iz
um
ab
2.
3%
M
ed
ia
n
PF
S
at
ez
ol
iz
um
ab
1.
4
m
on
th
s
O
RR
ch
em
ot
he
ra
py
10
%
M
ed
ia
n
PF
S
ch
em
ot
he
ra
py
4.
3
m
on
th
s
H
or
n,
20
18
[1
33
]
Ca
rb
op
la
tin
/E
to
po
si
de
+
at
ez
ol
iz
um
ab
or
pl
ac
eb
o
Ph
as
e
III
40
3
O
S
M
ed
ia
n
O
S
at
ez
ol
iz
um
ab
12
.3
m
on
th
s
M
ed
ia
n
O
S
co
nt
ro
la
rm
10
.3
m
on
th
s
H
R
0.
70
,9
5%
CI
0.
54
–0
.9
1,
p
=
0.
00
7
A
go
ni
st
ic
an
ti
bo
di
es
st
im
ul
at
in
g
th
e
im
m
un
e
sy
st
em
Th
om
as
,2
01
7
[1
38
]
M
ai
nt
en
an
ce
le
fit
ol
im
od
vs
ob
se
rv
at
io
n
Ph
as
e
II
O
pe
n
la
be
l
10
2
O
S
M
ed
ia
n
O
S
27
9
da
ys
(le
fit
ol
im
od
)
vs
27
2
da
ys
(c
on
tr
ol
)
H
R
1.
27
,9
5%
CI
0.
80
–2
.0
1,
p
=
0.
53
N
:N
um
be
r;
SC
LC
:
sm
al
l-c
el
l
lu
ng
ca
nc
er
;L
D
:l
im
ite
d
di
se
as
e;
ED
:e
xt
en
si
ve
di
se
as
e;
BC
G
:
Ba
ci
llu
s
Ca
lm
et
te
–G
ué
rin
;C
T:
ch
em
ot
he
ra
py
;
O
S:
ov
er
al
l
su
rv
iv
al
;
m
:m
on
th
s;
H
R
ha
za
rd
ra
tio
;C
I
co
nf
id
en
ce
in
te
rv
al
;T
RT
:t
ho
ra
ci
c
ra
di
ot
he
ra
py
;P
FS
:p
ro
gr
es
si
on
-f
re
e
su
rv
iv
al
;I
FN
:i
nt
er
fe
ro
n;
13
-C
RA
:1
3-
ci
s-
re
tin
oi
c
ac
id
;O
RR
:r
es
po
ns
e
ra
te
;P
D
-L
1:
pr
og
ra
m
m
ed
de
at
h-
lig
an
d
1.
160 L. E. L. HENDRIKS ET AL.
Ta
bl
e
4.
O
ng
oi
ng
tr
ia
ls
w
ith
im
m
un
e
th
er
ap
ie
s
in
SC
LC
.
Cl
in
ic
al
tr
ia
l.g
ov
nu
m
be
r
St
ag
e
Ph
as
e
Pr
im
ar
y
ob
je
ct
iv
e
Pr
im
ar
y
en
d
po
in
t
Tr
ea
tm
en
t
Lo
ca
tio
ns
Sp
on
so
r
V
ac
ci
na
ti
on
+
ch
ec
kp
oi
nt
in
hi
bi
to
r
tr
ia
ls
N
CT
03
40
67
15
ED
II
Ac
tiv
ity
D
CR
Ip
ili
m
um
ab
+
ni
vo
lu
m
ab
+
de
nd
rit
ic
ce
ll
ba
se
d
p5
3
va
cc
in
e
(A
d.
p5
3-
D
C)
Le
e
M
of
fit
t
Ca
nc
er
Ce
nt
er
an
d
Re
se
ar
ch
In
st
itu
te
BM
S
N
CT
02
68
86
73
ED
I/I
I
Ac
tiv
ity
O
RR
Ad
en
ov
iru
s-
tr
an
sf
ec
te
d
au
to
lo
go
us
D
C
va
cc
in
e
pl
us
CI
K
ce
lls
U
nk
no
w
n
Af
fil
ia
te
d
H
os
pi
ta
lt
o
Ac
ad
em
y
of
M
ili
ta
ry
M
ed
ic
al
Sc
ie
nc
es
C
he
ck
po
in
t
in
hi
bi
to
r
tr
ia
ls
in
LD
-S
C
LC
N
CT
02
04
67
33
LD
II
Ef
fic
ac
y
PF
S;
O
S
CR
T
→
ni
vo
lu
m
ab
+
ip
ili
m
um
ab
→
ni
vo
lu
m
ab
EU
ET
O
P
N
CT
02
40
29
20
LD
I
Sa
fe
ty
D
LT
CR
T
+
pe
m
br
ol
iz
um
ab
→
pe
m
br
ol
iz
um
ab
M
D
An
de
rs
on
M
D
An
de
rs
on
N
CT
03
58
59
98
LD
II
Ef
fic
ac
y
PF
S
CR
T
+
du
rv
al
um
ab
→
du
rv
al
um
ab
Sa
m
su
ng
M
ed
ic
al
Ce
nt
er
Sa
m
su
ng
M
ed
ic
al
Ce
nt
er
N
CT
03
54
04
20
LD
II
Ef
fic
ac
y
2y
O
S
CR
T
→
av
el
um
ab
vs
CR
T
N
or
w
ay
N
or
w
eg
ia
n
U
ni
ve
rs
ity
of
Sc
ie
nc
e
an
d
Te
ch
no
lo
gy
N
CT
03
50
90
12
LD
I
Sa
fe
ty
D
LT
●
D
ur
va
lu
m
ab
+
tr
em
el
im
um
ab
+
CT
●
D
ur
va
lu
m
ab
+
CR
T
●
D
ur
va
lu
m
ab
+
tr
em
el
im
um
ab
+
CR
T
W
or
ld
AZ
C
he
ck
po
in
t
in
hi
bi
to
r
fi
rs
t-
lin
e/
m
ai
nt
en
an
ce
ED
-S
C
LC
tr
ia
ls
N
CT
03
32
58
16
ED
I/I
I
Sa
fe
ty
RP
2D
;P
FS
N
iv
ol
um
ab
+
17
7L
u-
D
O
TA
0-
Ty
r3
-O
ct
re
ot
at
e
U
S
BM
S
N
CT
03
38
25
61
ED
II
Ef
fic
ac
y
PF
S
N
iv
ol
um
ab
+
CT
→
N
iv
ol
um
ab
vs
CT
U
S
N
CI
N
CT
02
53
86
66
ED
III
Ef
fic
ac
y
PF
S;
O
S
N
iv
ol
um
ab
vs
ni
vo
lu
m
ab
+
ip
ili
m
um
ab
vs
pl
ac
eb
o
W
or
ld
BM
S
N
CT
02
58
09
94
ED
II
Ef
fic
ac
y
PF
S
CT
+
Pe
m
br
ol
iz
um
ab
→
pe
m
br
ol
iz
um
ab
W
or
ld
EO
RT
C
N
CT
02
93
45
03
ED
I/I
I
Ac
tiv
ity
Ch
an
ge
PD
-L
1
ex
pr
es
si
on
CT
+
pe
m
br
ol
iz
um
ab
→
RT
CR
T
→
CT
+
pe
m
br
ol
iz
um
ab
CT
→
pe
m
br
ol
iz
um
ab
CR
T
→
pe
m
br
ol
iz
um
ab
N
Y
U
ni
ve
rs
ity
N
Y
U
ni
ve
rs
ity
N
CT
03
04
38
72
ED
III
Ef
fic
ac
y
PF
S;
O
S
D
ur
va
lu
m
ab
+
tr
em
el
im
um
ab
+
CT
vs
CT
W
or
ld
AZ
N
CT
02
65
82
14
ED
I
Sa
fe
ty
D
LT
D
ur
va
lu
m
ab
+
tr
em
el
im
um
ab
+
CT
W
or
ld
AZ
N
CT
03
56
80
97
ED
II
Ac
tiv
ity
1y
PF
S
Av
el
um
ab
+
CT
G
re
ec
e
H
el
le
ni
c
Co
op
er
at
iv
e
G
ro
up
N
CT
03
06
67
78
ED
III
Ef
fic
ac
y
O
S
CT
+
at
ez
ol
iz
um
ab
W
or
ld
Ro
ch
e
C
he
ck
po
in
t
in
hi
bi
to
r
se
co
nd
-l
in
e
an
d
be
yo
nd
ED
-S
C
LC
tr
ia
ls
N
CT
03
02
61
66
ED
I/I
I
Sa
fe
ty
D
LT
Ro
va
lp
itu
zu
m
ab
Te
si
rin
e
+
ni
vo
lu
m
ab
/
N
iv
ol
um
ab
+
ip
ili
m
um
ab
W
or
ld
Ab
bV
ie
N
CT
03
57
57
93
ED
I/I
I
Sa
fe
ty
M
TD
N
iv
ol
um
ab
+
ip
ili
m
um
ab
+
pl
in
ab
ul
in
Ru
tg
er
s
Ca
nc
er
In
st
itu
te
of
N
ew
Je
rs
ey
Ru
tg
er
s
Ca
nc
er
In
st
itu
te
of
N
ew
Je
rs
ey
N
CT
03
25
30
68
ED
II
Ac
tiv
ity
O
RR
Pe
m
br
ol
iz
um
ab
+
am
ru
bi
ci
ne
W
ak
ay
am
a
M
ed
ic
al
U
ni
ve
rs
ity
W
ak
ay
am
a
M
ed
ic
al
U
ni
ve
rs
ity
N
CT
03
40
28
80
ED
II
Ac
tiv
ity
O
RR
Pe
m
br
ol
iz
um
ab
+
ep
ac
ad
os
ta
t
U
S
Ci
ty
of
H
op
e
M
ed
ic
al
Ce
nt
er
N
CT
03
37
19
79
ED
I/I
I
Ac
tiv
ity
O
RR
Pe
gz
ila
rg
in
as
e
+
pe
m
br
ol
iz
um
ab
U
S
Ae
gl
ea
Bi
ot
he
ra
pe
ut
ic
s
N
CT
02
70
14
00
ED
II
Ef
fic
ac
y
PF
S
D
ur
va
lu
m
ab
+
tr
em
el
im
um
ab
+
RT
Em
or
y
U
ni
ve
rs
ity
AZ
N
CT
03
08
58
49
ED
I
Sa
fe
ty
D
LT
SG
I-1
10
→
D
ur
va
lu
m
ab
+
tr
em
el
im
um
ab
U
ni
ve
rs
ity
Co
lu
m
bi
a
U
ni
ve
rs
ity
N
CT
02
73
40
04
ED
I/I
I
Ac
tiv
ity
O
RR
O
la
pa
rib
+
du
rv
al
um
ab
W
or
ld
AZ
N
CT
02
73
40
04
ED
I/I
I
Ac
tiv
ity
D
CR
●
O
la
pa
rib
+
du
rv
al
um
ab
●
O
la
pa
rib
+
du
rv
al
um
ab
+
be
va
ci
zu
m
ab
W
or
ld
AZ
N
CT
02
93
78
18
ED
II
Ac
tiv
ity
O
RR
●
D
ur
va
lu
m
ab
+
tr
em
el
im
um
ab
●
AZ
D
17
75
an
d
ca
rb
op
la
tin
●
AZ
D
67
38
+
ol
ap
ar
ib
EU
AZ
N
CT
03
26
24
54
ED
II
Ac
tiv
ity
O
RR
RT
→
at
ez
ol
iz
um
ab
Ko
re
a
N
CC
Ko
re
a
ED
:E
xt
en
si
ve
di
se
as
e;
LD
:l
im
ite
d
di
se
as
e;
D
CR
:d
is
ea
se
co
nt
ro
l
ra
te
;
O
RR
:o
bj
ec
tiv
e
re
sp
on
se
ra
te
;B
M
S:
Br
is
to
l–
M
ye
rs
Sq
ui
bb
;P
FS
:p
ro
gr
es
si
on
-f
re
e
su
rv
iv
al
;O
S:
ov
er
al
l
su
rv
iv
al
;C
RT
:c
he
m
or
ad
ia
tio
n;
EU
:E
ur
op
ea
n
U
ni
on
;
ET
O
P:
Eu
ro
pe
an
Th
or
ac
ic
O
nc
ol
og
y
Pl
at
fo
rm
;
D
LT
:
do
se
-li
m
iti
ng
to
xi
ci
ty
;
CT
:
ch
em
ot
he
ra
py
;
AZ
:
As
tr
aZ
en
ec
a;
RP
2D
:
re
co
m
m
en
de
d
ph
as
e
2
do
se
;
U
S:
U
ni
te
d
St
at
es
;
N
CI
:
N
at
io
na
l
Ca
nc
er
In
st
itu
te
;
EO
RT
C:
Eu
ro
pe
an
O
rg
an
iz
at
io
n
fo
r
Re
se
ar
ch
an
d
Tr
ea
tm
en
t
of
Ca
nc
er
;P
D
-L
1:
pr
og
ra
m
m
ed
de
at
h-
Li
ga
nd
1;
N
Y:
N
ew
Yo
rk
;y
:y
ea
r;
CI
K:
cy
to
ki
ne
-in
du
ce
d
ki
lle
r;
M
T:
m
ax
im
um
-t
ol
er
at
ed
do
se
;O
RR
:o
bj
ec
tiv
e
re
sp
on
se
ra
te
;N
CC
:n
at
io
na
lc
an
ce
r
ce
nt
er
.
EXPERT REVIEW OF ANTICANCER THERAPY 161
vaccination and responses were linked to induction of immu-
nologic response to vaccination [124].
Several other vaccination trials are ongoing (Table 4).
3.3.2. Immunotherapy trials
As described in Section 2, trials with monotherapy Bcl-2 inhi-
bition have been disappointing. In a phase II trial, IFN-alfa was
added to the Bcl-2-modifying agent 13-cis-retinoic acid (13-
CRA) and paclitaxel. Primary end point was ORR. Thirty-seven
relapsed ED-SCLCs were enrolled and were treated with
IFN-alfa (6 million units/m2 subcutaneously) and 13-CRA
1 mg/kg days 1 and 2, and paclitaxel 75 mg/m2 iv on day 2
of each week for 6 weeks of an 8-week schedule. ORR was only
9% and PFS was only 2 months. Therefore, this combination is
not further studied [125].
Checkpoint inhibitors (anti-PD-(L)1 and anti-CTLA4) have
shown efficacy in SCLC in some (early phase) trials but other
trials were negative. Results are summarized below.
Ipilimumab, a CTLA-4 inhibitor, did not result in an
improved OS when added to platinum–etoposide in a first-
line, double-blind, randomized phase III trial (NCT01450761).
Primary end point was OS among patients that received at
least one dose of study therapy. About 1132 treatment-naive
ED-SCLCs were randomized to platinum-doublet chemother-
apy with phased ipilimumab 10 mg/kg every 3 weeks (start at
cycle 3 of chemotherapy till cycle 6). A total of 954 patients
received at least 1 dose of ipilimumab/placebo. The trial was
negative: median OS was 11.0 months for the experimental
arm and 10.9 months for the standard treatment (HR 0.94,
95% CI 0.81–1.09, p = 0.38). Except for diarrhea, rash, and
colitis, rates and severity of treatment-related adverse-events
were similar for both groups. However, treatment discontinua-
tion occurred more often in the investigational arm (18% vs
2%) [126].
A phase I trial (KEYNOTE-028, NCT02054806) with pembro-
lizumab (PD-L1 inhibitor, 10 mg/kg every 2 weeks for up to
24 weeks) showed promising results in pretreated, PD-L1
expressing (≥1%) SCLC patients (N = 24). ORR was 33%, med-
ian PFS was only 1.9 months but response was durable in
responding patients (DOR 19.4 months). Median OS was
9.7 months. One patient had a grade 5 colitis, and another
had a grade 3 bilirubin elevation. No other grade 3–5 adverse
events were observed [127]. However, pembrolizumab main-
tenance therapy failed to improve PFS in a single-arm, phase II
trial (NCT02359091) with 45 patients. Median PFS was only
1.4 months, RR was 11.8%, and median OS was 9.6 months.
The small subgroup of PD-L1-positive patients (N = 9) had a
higher PFS compared with the PD-L1-negative patients (6.5 vs
1.3 months) [128]. Pembrolizumab monotherapy (200 mg iv
every 3 weeks for up to 2 years) was also evaluated in the
second-line and beyond phase II basket study KEYNOTE-158.
Patients were selected regardless of biomarker status. Primary
end point was ORR. About 107 patients were enrolled in the
SCLC cohort, and 14% was PD-L1 positive (≥1%). ORR was
18.7% and 30% had disease control. ORR was higher in the
PD-L1 positive cohort (N = 42) compared to the PD-L1 nega-
tive cohort (N = 50) and was 35.7% vs 6.0%. Median DOR was
not reached; median PFS was 2.0 months and was similar for
both PD-L1 status cohorts. Median OS was higher for the
PD-L1-positive cohort and was 14.9 vs 5.9 months. About
13% had grade 3–4 treatment-related adverse events [129].
Durvalumab monotherapy (10 mg/kg iv every 2 weeks for
up to 12 months) has also been evaluated in a phase I/II trial
including a cohort of relapsed, unselected SCLC patients
(N = 21). ORR was only 9.5%; median PFS was 1.5 months
with a median OS of 4.8 months. However, DOR for the two
responding patients was 14.6 and 29.5+ months. No new
safety signals were observed [130]. Last, atezolizumab mono-
therapy (1200 mg iv every 3 weeks) has been compared to
standard chemotherapy as second-line treatment for ED-SCLC
in the randomized, noncomparative phase II IFCT-1603 trial
(N = 73). For atezolizumab, ORR was 2.3% with a median PFS
of 1.4 months. For chemotherapy, ORR was 10% with a median
PFS of 4.3 months [131].
It is possible that the limited tumor expression of PD-L1
combined with an exhausted immune cell phenotype contri-
butes to the limited activity of monotherapy checkpoint inhi-
bition [132]. The combination of PD-L1 inhibition with
chemotherapy or CTLA-4 inhibition is more promising in
SCLC. The combination of PD-L1 inhibition with chemotherapy
improved OS of treatment-naive ED-SCLC (N = 403) in the
randomized phase III IMpower 133 trial. Patients were rando-
mized between carboplatin/etoposide/atezolizumab followed
by maintenance atezolizumab or carboplatin/etoposide/pla-
cebo followed by maintenance placebo. Atezolizumab was
given at a flat dose of 1200 mg every 3 weeks. Median OS
was 12.3 months for the atezolizumab arm and 10.3 months
for the control arm (HR 0.70, 95% CI 0.54–0.91, p = 0.007).
Compared to previous safety findings of the individual agents,
no new safety signals were observed with the combination
[133]. The phase III KEYNOTE 604 trial (NCT03066778) with a
similar design as the IMpower133 (pembrolizumab 200 mg flat
dose instead of atezolizumab) is currently enrolling patients.
Data with PD-L1 and CTLA-4 inhibition combined are also
interesting. For example, in the non-randomized phase I/II
CHECKMATE-032 trial (NCT01928394) including relapsed
SCLC patients (N = 216), RR with monotherapy nivolumab
(3 mg/kg every 2 weeks) was 10%, but RR with nivolumab
plus ipilimumab (1 plus 1 mg/kg, 1 plus 3 mg/kg, or 3 plus
1 mg/kg iv every 3 weeks for 4 cycles followed by nivolumab
monotherapy 3 mg/kg every 2 weeks) ranged from 19% to
33%. Responses were in both groups durable; median DOR
was 14.2–17.9 months. PD-L1 expression was not associated
with response [134]. In the randomized expansion cohort of
this trial, similar results were obtained. Grade 3–4 adverse
events were higher with the combination therapy [135]. In
an exploratory analysis of this trial, 211 patients (53%) were
evaluable for TMB (measured with whole exome sequencing)
and patients were divided in tertiles according to TMB value.
Outcomes in the TMB-evaluable population were similar com-
pared with the intention-to-treat population. ORR for high
TMB patients compared to low/medium TMB patients was
higher in the nivolumab monotherapy group and in the nivo-
lumab/ipilimumab group (21.3% vs 4.8–6.8% and 46.2% vs
22.2–16.0%, respectively). For nivolumab monotherapy, med-
ian PFS was similar across the TMB tertiles (1.3, 1.3, and
1.4 months). However, for nivolumab/ipilimumab, median
PFS was higher for the TMB-high group compared with the
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TMB low/medium groups (7.8 vs 1.5–1.3 months). Median OS
was also higher for the nivolumab/ipilimumab TMB-high
group: 22.0 vs 3.4–3.6 months [136]. In the phase II BALTIC
trial (cohort A), durvalumab 1500 mg iv and tremelimumab
75 mg iv every 4 weeks for up to 4 months, followed by
maintenance durvalumab 1500 mg iv every 4 weeks were
evaluated in platinum-refractory/resistant ED-SCLC (N = 21).
ORR was 9.5% with a median PFS of 1.9 months and a median
OS of 6.0 months. Twelve-month OS was 32.7%. Grade ≥3
treatment-related AEs occurred in 9.5%, including one fatal
hemorrhagic enterocolitis [137].
PD-L1 and CTLA-4 inhibitors combined with chemotherapy
are currently being tested in the phase III CASPIAN trial
(NCT03043872, platinum/etoposide vs durvalumab/platinum/
etoposide vs durvalumab/tremelimumab/platinum/etoposide).
Furthermore, multiple other checkpoint inhibitor trials are
ongoing in SCLC and are summarized in Table 4.
Agonistic antibodies are another method of stimulating the
immune system. Lefitolimod, a TLR9 agonist, targets TLR9
positive cells and activates both the innate and adaptive
immune system. In subgroup analyses of a maintenance ran-
domized phase II trial (NCT02200081) including SCLC patients
who responded to first-line platinum-doublet chemotherapy,
interesting results were found. Median OS was not signifi-
cantly different for the total study population (N = 102,
279 days for lefitolimod, 272 days for the control arm, HR
1.27, 95% CI 0.80–2.01, p = 0.53), but results were promising
although not significantly different in the predefined sub-
group of COPD patients (median OS 316 vs 246 days, HR
0.54, 95% CI 0.21–1.38). Promising results were also found in
the predefined subgroup of patients with baseline low num-
ber of activated B cells (median OS 284 vs 231 days, HR 0.59,
95% CI 0.29–1.21) [138].
4. Conclusion
SCLC is a tumor with a poor prognosis, mainly diagnosed in an
advanced stage as screening is not effective due to its high
aggressiveness. Smoking cessation is the best method to pre-
vent SCLC development.
Despite aggressive treatment of early and locally advanced
disease, SCLC often relapses. First-line chemotherapy provides
good RRs in advanced disease, but PFS and OS are limited.
Targetable molecular aberrations are very rare in SCLC and
almost all attempts made so far have been unsuccessful,
although Rova-T and anlotinib are more promising. New
drugs such as immune checkpoint inhibition are promising
in SCLC, especially in combination with chemotherapy, but
still more data and better predictive markers are needed.
5. Expert commentary
The prognosis of most SCLC patients is still poor, despite the
steps forward in SCLC molecular characterization, and the
(small) improvements in systemic treatment.
The lack of identification of clear prognostic and predictive
biomarkers has limited the advances in treatment efficacy. This
has most likely determined the failure in the development of
most compounds tested so far. One of the reasons that might
have contributed is the absence of an adequate amount of
tissue material for analysis, since the diagnosis is mostly by
cytology. On the other hand, the complex tumor biology with
the co-activation of several pathways and the rapid develop-
ment of resistance is also a challenge. Moreover, tumor het-
erogeneity, not yet well studied for this particular lung cancer
type, could play a key role in this disease and this needs to be
further explored.
In this scenario, liquid biopsy could represent a solution to
hopefully provide further data to better characterize and
monitor this disease.
Due to its highly mutational profile and rapid growth pat-
tern, immunotherapy combinations could be another step
forward in SCLC treatment. The phase III IMpower133 study
combining atezolizumab with carboplatin and etoposide is the
first phase III trial in about 20 years reporting a significant
improvement (although modest) in OS [133]. Multiple other
combination trials are ongoing, but the main research focus
should be defining which patients benefit most from a specific
combination therapy (e.g. PD-(L)1 inhibition combined with
chemotherapy, PD-(L)1 and CTLA4 combinations with or with-
out chemotherapy, and other combinations). Particularly, toxi-
city should also be thoroughly evaluated.
Other challenges will be, both for LD and ED-SCLC, the
identification of the best treatment sequence and the evalua-
tion of the potential efficacy of rechallenging immunotherapy.
Academic trials could represent the best way to test the
sequential strategy in order to finally provide clinicians the
support needed to treat patients in every-day clinic. The ulti-
mate goal is to prolong OS, and maintain/improve quality of
life, without a too high financial toxicity.
Crucial fields in the next future will also certainly be the
control of paraneoplastic syndromes, quite frequent in these
patients [110], as well as the control and treatment of brain
metastases [139], very frequently present already at diagnosis,
but also often a site of disease progression. Unfortunately,
SCLC patients with brain metastases are underrepresented in
clinical trials (e.g. only 8.5% brain metastases in the atezolizu-
mab arm of the IMpower133 study) [133].
The achievements made so far with targeted agents are
small, and most of the compounds tested did not shown any
benefit in activity or efficacy [28,70]. More promising are com-
binations with DLL3-antibodies or PARPi that could potentially
overcome mechanisms of resistance resulting hopefully in a
meaningful clinical benefit.
The results of antiangiogenic drugs have been rather dis-
appointing so far, but potential combinations with targeted
agents and/or immunotherapy are currently tested in clinical
trials, and results should be awaited before cutting off the
development of these compounds in this tumor type.
Hopefully the improved treatments in ED-SCLC also translate
to improved survival in LD-SCLC when tested in this setting.
6. Five-year view
In the coming years, we expect the focus of clinical research to
be on (1) predictive factors for immunotherapy, (2) the identi-
fication of mechanisms of resistance to immunotherapy and
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how to overcome them, and (3) the best treatment sequence
strategies.
Moreover, preclinical and clinical research should focus on
better understanding the crosstalk signaling pathways so as to
finally manage targeted agents correctly.
Key issues
● SCLC patients usually have a small amount of tissue to be
analyzed, limiting therefore translational research
● There is a clear lack of prognostic and predictive biomarkers
in this rapidly evolving disease
● Targeted therapies have failed to improve outcome,
although newer therapies such as PARPi and DLL3-antibo-
dies are promising
● Immunotherapy combinations can improve long-term out-
come in SCLC, but better predictive markers need to be
identified so to develop the best treatment strategy and
sequence
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